



FOR IMMEDIATE RELEASE.....

**XetaComp Receives Second Oklahoma  
Nanotechnology Commercialization Award**

Edmond, OK (April 23, 2008): A two-year \$344,800 grant has been awarded to XetaComp Nanotechnology LLC, a wholly-owned subsidiary of NanoBioMagnetics, Inc., (NBMI) by the Oklahoma Center for the Advancement of Science and Technology (OCAST).

The grant was one of the two largest among \$1.25 million in state funds awarded to eight Oklahoma companies active in nanotechnology. XetaComp also had been awarded a \$250,000 grant in the first Nanotechnology Applications Project awards last year.

XetaComp, with offices and manufacturing facilities in Lawton, Oklahoma, was established by NBMI in 2006 to develop and market a range of functionalized nanomaterials. The company's initial commercial target is a broad-spectrum UVA/UVB physical sunscreen, on which a line of dermal care products are based, and now being introduced under the **sunVex**<sup>®</sup> Trademark, as cancer prevention tools. The technology for **sunVex**<sup>®</sup> is based on a proprietary nanofabrication process that yields a surface-treated titanium dioxide nanomaterial. The company's technology offers the marketplace high-performance UVA/UVB attenuation along with cost-effective economics.

Charles Seeney, CEO and Founder of NBMI, said the infusion of working capital is important to XetaComp's product development and commercialization efforts. "There has been tremendous interest in both **sunVex**<sup>®</sup> intermediates and dermal care products, and the timing of this grant is highly meaningful to our success in bringing these products onto the market," he said.

"The efforts of ONAP and OCAST's executive director Michael Carolina are achieving significant results in positioning Oklahoma as an emerging leader in nanotechnology," Seeney said.

NanoBioMagnetics, Inc., with offices and research facilities in Edmond, Oklahoma, is a nanobiomaterials development company pioneering an emerging area of nanomedicine referred to as Organ-Assisting-Device (OAD) technologies. As these healthcare technologies are developed and validated, NBMI's business model calls for them to be spun-off as separate business units manufacture and commercialization, and XetaComp was organized as the first of these spinoffs.

###

Contact: Charles E Seeney  
(405) 844-5118  
nanobio@nanobmi.com